Leadership & Pay ·
Aardvark Therapeutics appoints David Zhang to its Board of Directors
AARDAardvark Therapeutics, Inc.
The board appointed David Zhang, Ph.D., MBA, as a Class II director effective October 7, 2026. Dr. Zhang brings over 25 years of experience in clinical strategy and biostatistics from roles at Abivax S.A., Alumis Inc., MyoKardia, and Genentech/Roche. He receives $40,000 annually plus a stock option valued at $500,000 that vests monthly over three years with full acceleration upon a change in control. Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for metabolic diseases and Prader-Willi Syndrome.